Kate Jackson, Breast Cancer, and the Value of Early Detection

What Kate Jackson has said

Kate Jackson, one of the original stars of "Charlie's Angels," was diagnosed with breast cancer in 1987. It returned in 1989, and she had a partial mastectomy. TV Insider, reporting on a 2026 cast reunion, laid out that timeline.

Jackson has kept one message steady for decades. In 2026 she told TODAY: "It's really important to understand and embrace not being afraid of getting a mammogram. Early detection is key. Find it early enough and you'll probably be all right."

Her private medical details are hers. The idea behind her message is public property, and it holds up. But it deserves a fuller answer than a slogan, because screening is a real medical decision with real numbers on both sides.

Where breast cancer starts

The breast is built from ducts, which carry milk, and lobules, which make it. Cancer usually begins in the lining of one of those two structures.

The National Cancer Institute reports that invasive ductal carcinoma is the most common type, making up 70% to 80% of cases. Invasive lobular carcinoma accounts for 10% to 15%. Lobular cancer behaves differently. It tends to grow in single-file lines rather than as a lump, which is one reason it can be harder to feel and harder to see on a mammogram.

"In situ" means the abnormal cells are still inside the duct or lobule and have not broken through the wall. NCI's PDQ summary carries an American Cancer Society count of 59,080 cases of female ductal carcinoma in situ in the United States in 2025. Lobular carcinoma in situ is different again. NCI notes it has been removed from TNM staging and is now considered a benign entity, meaning a risk marker rather than a cancer.

What screening actually buys, in numbers

The U.S. Preventive Services Task Force recommends biennial screening mammography for women aged 40 to 74 years. That is a grade B recommendation, issued April 30, 2024. Biennial means every two years.

NCI's guidance for clinicians is more granular about how much good it does. Screening mammography reduces breast cancer deaths, with solid evidence for women aged 60 to 69 and fair evidence for women aged 50 to 59. The benefit is real, and it grows with age.

NCI also states how many women must be screened to prevent one breast cancer death:

• Ages 39 to 49: about 1,904 women.
• Ages 50 to 59: about 1,339 women.
• Ages 60 to 69: about 377 women.

The other side of the ledger

Honest screening information includes the costs. NCI's clinician guidance is blunt about them.

About 10% of American women are called back for more testing after a screening mammogram. Only 0.5% of women tested actually have cancer. Roughly half of women screened every year for ten years will get at least one false-positive result, and 7% to 17% of those women go on to have a biopsy.

Then there is overdiagnosis. NCI estimates that between 20% and 50% of screen-detected cancers represent overdiagnosis, meaning tumors found that would never have caused symptoms or harm in that person's lifetime. Nobody can tell in advance which ones those are, so they get treated.

None of that is an argument against screening. It is the reason the recommendation says every two years rather than every year, and the reason the age range starts at 40 rather than 30. Knowing both columns makes the decision yours instead of somebody else's.

When to get checked between mammograms

A normal mammogram is not a permission slip to ignore a change. NCI says plainly that you should follow up with a doctor when you notice a breast change, even if you had a recent normal mammogram.

Get these looked at:

• A lump or a thick, firm area in or near the breast, or under the arm.
• A change in the size or shape of one breast.
• Fluid or discharge from the nipple that is not breast milk.
• A nipple that flattens, inverts, or changes the direction it points.
• Scaly, swollen, red, or darkened skin on the breast, nipple, or areola.
• Dimpling or puckering of the skin, or a rash on the breast.
• Swelling of the whole breast, with no lump at all.
• Itching or tingling in the nipple or areola.

One point catches people out. NCI states that breast cancer does not usually cause pain. Waiting for a lump to start hurting is not a safe test.

What happens after something shows up

Screening finds a question. A diagnosis answers it. NCI describes the path.

A diagnostic mammogram takes more targeted images. Ultrasound uses sound waves and is good at telling a fluid-filled cyst from a solid mass.

Then tissue. NCI is direct: a biopsy is the only sure way to diagnose breast cancer. A fine-needle aspiration uses a thin needle, a core-needle biopsy uses a wider one, and image guidance steers either into the right spot. Sometimes part of a lump is removed, or all of it.

The biopsy sample does more than confirm cancer. NCI states that all breast cancers are tested for hormone receptors, meaning estrogen and progesterone receptors, and for HER2. Those results decide whether endocrine therapy or HER2-directed drugs will work at all. Tumor grade is scored from 1 to 3, where 1 looks closest to normal tissue. Multigene tests such as Oncotype DX and MammaPrint can estimate the risk of recurrence and help decide about chemotherapy.

Stage comes from the TNM system. NCI's clinician guidance sets tumor size categories at 20 mm or less for T1, more than 20 up to 50 mm for T2, more than 50 mm for T3, and any size involving the chest wall or skin for T4.

What the survival picture looks like for a group

These are population figures. They summarize hundreds of thousands of women and describe no individual.

SEER, the federal cancer statistics program, publishes an American Cancer Society projection of 321,910 new female breast cancers in the United States in 2026, about 15.2% of all new cancer diagnoses, and 42,140 deaths. Five-year relative survival across all stages is 91.9% for women diagnosed between 2016 and 2022. The median age at diagnosis is 64.

Stage drives the difference. SEER records five-year relative survival of 100.0% for localized disease, 87.5% once it has reached nearby nodes, and 33.8% once it has spread to distant organs. About 64% of cases are found while still localized.

That is the arithmetic behind Jackson's sentence about early detection. It does not promise anything to a particular person. It does explain why the appointment is worth keeping.

Sources

• NCI: Breast Cancer Treatment (PDQ) — Health Professional Version
• NCI: Breast Cancer Screening (PDQ) — Health Professional Version
• NCI: Signs and Symptoms of Breast Cancer
• NCI: How Is Breast Cancer Diagnosed?
• SEER Cancer Stat Facts: Female Breast Cancer
• American Cancer Society: Cancer Facts & Figures
• USPSTF: Breast Cancer Screening, final recommendation, April 30, 2024
• NBC Boston: Stars of 'Charlie's Angels' all survived breast cancer
• TV Insider: 'Charlie's Angels' Stars Reflect on Cancer Journeys